Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A

1st Edition - October 21, 2021

Write a review

  • Editors: Niccolo Bartalucci, Lorenzo Galluzzi
  • eBook ISBN: 9780323899406
  • Hardcover ISBN: 9780323899390

Purchase options

Purchase options
DRM-free (PDF, EPub)
Available
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A, Volume 365 in the International Review of Cell and Molecular Biology series reviews and details current advances in cell and molecular biology. Chapters in this new release include MPN a continuum of different disease entities, Bone marrow microenvironment of MPN, Extramedullary hemopoiesis in MPN, The JAK2 mutation, Calreticulin mutations in myeloproliferative neoplasms, and Cytogenetic abnormalities and non-driver mutations in MPN. The IRCMB series has a worldwide readership, maintaining a high standard by publishing invited articles on important and timely topics that are authored by prominent cell and molecular biologists. The articles published in IRCMB have a high impact and an average cited half-life of 9 years. This great resource ranks high amongst scientific journals dealing with cell biology.

Key Features

  • Publishes only invited review articles on selected topics
  • Authored by established and active cell and molecular biologists and drawn from international sources
  • Offers a wide range of perspectives on specific subjects

Readership

The IRCMB series covers all fields of cell and molecular biology. IRCMB articles are addressed to a very wide public, ranging from undergraduate and graduate students to experienced scientists in a specific field.

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Contributors
  • Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
  • References
  • Chapter One: Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
  • Abstract
  • 2: Clinical characteristics of MPNs
  • 3: Genetics of MPNs
  • 4: Diagnostic criteria of MPNs
  • 5: Clinical and molecular-integrated prognostic scores in MPNs
  • 6: Current standard treatment in MPNs
  • 7: Evolving therapies and clinical trials in MPNs
  • References
  • Acknowledgments
  • Chapter Two: Bone marrow microenvironment of MPN cells
  • Abstract
  • 1: Introduction
  • 2: The bone marrow niche in myeloproliferative neoplasms
  • 3: The bone marrow extracellular matrix components in MPNs
  • 4: Conclusions
  • References
  • Chapter Three: Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies
  • Abstract
  • 1: Introduction
  • 2: Extramedullary hematopoiesis
  • 3: Pathophysiology of EMH
  • 4: Therapeutic strategies
  • 5: JAK inhibitors
  • 6: Radiation and surgical intervention
  • 7: Hematopoietic stem cell transplant (HSCT)
  • 8: Non-JAK inhibitor pharmaceutical approaches
  • 9: Emerging research
  • 10: Conclusion
  • References
  • Chapter Four: The JAK2 mutation
  • Abstract
  • 1: JAK2: A non-receptor tyrosine kinase
  • 2: JAK2 mutations in Ph-myeloproliferative neoplasms
  • 3: Aberrant signaling downstream of JAK2V617F
  • 4: Factors determining phenotypes in JAK2V617F-positive MPNs
  • 5: Cellular effects of JAK2V617F
  • 6: Concluding remarks
  • References
  • Chapter Five: The MPL mutation
  • Abstract
  • 1: Thrombopoietin receptor-MPL physiology
  • 2: MPL mutations in myeloproliferative neoplasms
  • References
  • Chapter Six: Calreticulin mutations in myeloproliferative neoplasms
  • Abstract
  • 1: Function of calreticulin
  • 2: CALR mutations
  • 3: Clinical features of CALR-mutant MPN
  • 4: Molecular mechanism of MPL activation
  • 5: CALR mutation and disruption of intracellular homeostasis
  • 6: Effects on stem cells and cell differentiation
  • 7: Disruption of the immune system
  • 8: Treatment targeting mutant CALR protein
  • 9: Remaining questions
  • 10: Toward a breakthrough in MPN treatment
  • References

Product details

  • No. of pages: 248
  • Language: English
  • Copyright: © Academic Press 2021
  • Published: October 21, 2021
  • Imprint: Academic Press
  • eBook ISBN: 9780323899406
  • Hardcover ISBN: 9780323899390

About the Serial Volume Editors

Niccolo Bartalucci

Niccolo Bartalucci practices in Florence, Italy. Dr. Bartalucci is highly rated in 6 conditions, according to our data. His top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera, and Splenomegaly. His clinical research consists of co-authoring 34 peer reviewed articles in the past 15 years.

Affiliations and Expertise

Department of Experimental and Clinical Medicine, University of Florence, Italy

Lorenzo Galluzzi

Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and Expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A"